Status:
COMPLETED
Pathophysiology of Uric Acid Nephrolithiasis
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Takeda Pharmaceuticals North America, Inc.
Conditions:
Uric Acid Kidney Stone Disease
Eligibility:
All Genders
21-99 years
Phase:
NA
Brief Summary
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test r...
Detailed Description
The study will use a combination of cell culture, animal, and human studies employing some of the latest technologies in magnetic resonance spectroscopy and single-photon emission computed tomography,...
Eligibility Criteria
Inclusion
- Subjects with uric acid kidney stone disease
- Age \> 21 years
Exclusion
- Body weight\> 350 lb
- Chronic alcohol use
- Chronic liver disease
- Chronic renal disease
- Anemia
- Contraindication to pioglitazone use:
- history of congestive heart failure NYHA class III or IV
- significant pedal edema
- liver failure
- not willing to practice an effective contraception for the duration of the study
- Thiazolidinedione use in the preceding 18 months
Key Trial Info
Start Date :
January 15 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 16 2017
Estimated Enrollment :
172 Patients enrolled
Trial Details
Trial ID
NCT00904046
Start Date
January 15 2010
End Date
November 16 2017
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UT Southwestern Medical Center - Center for Mineral Metabolism
Dallas, Texas, United States, 75390-8885